KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Weighted Average and Diluted) (2010 - 2026)

Sarepta Therapeutics' quarterly EPS (Weighted Average and Diluted) came in at $2.88 in Q1 2026, up 162.61% year-on-year from $1.1 in Q1 2025, and up 173.28% quarter-over-quarter from -$3.93 in Q4 2025.

Sarepta Therapeutics has reported EPS (Weighted Average and Diluted) for 13 years, with the latest figure at $2.88 in Q1 2026.

  • For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 162.61% year-over-year to $2.88; the trailing twelve-month figure through Mar 2026 stood at $0.34 (up 112.64% YoY), and the FY2025 full-year result was -$7.13, down 404.7% from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 stood at $2.88, up from -$3.93 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $2.88 in Q1 2026, with the low at -$4.6 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.59, with a median of -$0.27 recorded in 2023.
  • Peak annual rise in EPS (Weighted Average and Diluted) reached 2600.0% in 2025, while the deepest fall reached 1343.24% in 2025.
  • Tracing SRPT's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.24 in 2022, then jumped by 161.29% to $0.76 in 2023, then surged by 97.37% to $1.5 in 2024, then slumped by 362.0% to -$3.93 in 2025, then surged by 173.28% to $2.88 in 2026.
  • The last three EPS (Weighted Average and Diluted) figures came in at $2.88 (Q1 2026), -$3.93 (Q4 2025), and -$0.5 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Sarepta Therapeutics 1.86 Bn 1.17 Bn 291.52 Mn 2.88

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 2.88
Dec 31, 2025 -3.93
Sep 30, 2025 -0.50
Jun 30, 2025 1.89
Mar 31, 2025 -4.60
Dec 31, 2024 1.50
Sep 30, 2024 0.34
Jun 30, 2024 0.07
Mar 31, 2024 0.37
Dec 31, 2023 0.76
Sep 30, 2023 -0.46
Jun 30, 2023 -0.27
Dec 31, 2022 -1.24
Sep 30, 2022 -2.94
Jun 30, 2022 -2.65
Dec 31, 2021 -1.43
Sep 30, 2021 -0.60
Jun 30, 2021 -1.02
Jun 30, 2018 -1.67
Mar 31, 2018 -0.55
Jun 30, 2017 -1.15
Mar 31, 2017 1.50
Jun 30, 2016 -1.35
Mar 31, 2016 -1.31
Sep 30, 2013 -1.24
Jun 30, 2013 -0.60
Sep 30, 2012 -2.17
Jun 30, 2012 0.35
Mar 31, 2012 -0.13
Dec 31, 2011 0.02
Sep 30, 2011 -0.18
Jun 30, 2011 0.06
Mar 31, 2011 0.02
Dec 31, 2010 -0.01
Jun 30, 2010 -0.15